Results for: Jim Cramer

On CNBC’s ‘Mad Money Lightning Round,’ Jim Cramer shared his insights on Target, Zoetis, PROCEPT BioRobotics, and Consolidated Edison. He praised Target’s strong second-quarter performance and Zoetis’s impressive financial results. While he highlighted the growth potential of PROCEPT BioRobotics, he recommended investors consider Intuitive Surgical (ISRG) instead for robotics investments. Cramer also expressed his continued confidence in Consolidated Edison, citing its consistent performance and attractive dividend yield.

Jim Cramer, host of CNBC’s ‘Mad Money,’ advises investors not to panic sell Nvidia stock despite the recent DOJ antitrust investigation. While acknowledging potential for further decline, Cramer emphasizes that Nvidia has faced similar scrutiny before and urges investors to review past instances. He cautions against selling based solely on the subpoena, highlighting the company’s strong long-term prospects driven by its AI capabilities.

On CNBC’s ‘Mad Money Lightning Round’, Jim Cramer shared his insights on three companies: ADMA Biologics, MP Materials, and Delcath Systems. He expressed cautious optimism about ADMA Biologics, acknowledged the challenges facing MP Materials, and advised against investing in Delcath Systems.

Jim Cramer, host of CNBC’s ‘Mad Money,’ expressed optimism about Lululemon Athletica and Dell Technologies, citing potential bottoming for Lululemon and strong performance for Dell. Both companies recently released their second-quarter earnings reports, showing mixed results. However, Cramer’s positive outlook comes amidst a broader market rally and positive economic data.

CNBC’s Jim Cramer defended Nvidia after its stock price dropped following strong second-quarter earnings, calling out investors who sold shares they didn’t fully understand. He believes this decline will allow Nvidia to focus on its core business and future growth, despite challenges like high expectations and customer understanding of its technology.

Jim Cramer, host of CNBC’s ‘Mad Money,’ believes Nvidia’s upcoming earnings report will showcase the company’s significant growth potential in the AI sector, despite recent market fluctuations. He suggests investors look beyond short-term volatility and focus on Nvidia’s long-term prospects, comparing the company to a biotech firm due to its transformative AI technologies.

Jim Cramer, host of CNBC’s ‘Mad Money,’ offered his insights on various stocks in his Lightning Round segment. He recommended buying more Micron Technology, holding Crane Company, selling some Iron Mountain, owning Devon Energy, and preferring Arm Holdings over Intel. He also expressed his opinion on L3Harris Technologies.

Jim Cramer, host of CNBC’s ‘Mad Money,’ believes the recent market surge may be nearing an end due to overbuying and a shift from optimism to reality. Cramer expects the market to pause and recharge before another rally, with investors anticipating Jerome Powell’s speech at the Jackson Hole conference on Friday. The Nasdaq 100 experienced a significant decline on Thursday due to concerns surrounding interest rates and the overall economic outlook.

Jim Cramer, host of CNBC’s ‘Mad Money,’ discusses the recent Starbucks CEO change and its implications for investors. The appointment of Brian Niccol, former CEO of Chipotle, has sparked a surge in Starbucks’ stock valuation, reflecting investor optimism about the company’s future. Cramer acknowledges the challenges ahead but expresses confidence in Niccol’s ability to lead the company toward growth.

In a recent episode of CNBC’s ‘Mad Money Lightning Round,’ Jim Cramer shared his thoughts on several stocks, including Ally Financial, Snowflake, Royalty Pharma, and Core Scientific. Cramer recommended buying Ally Financial but was hesitant on Snowflake due to recent downgrades. He expressed disappointment with Royalty Pharma’s performance and labeled Core Scientific as overvalued.